SCHEMBL5230601

SCHEMBL5230601

C/C(=C/C(=C(C#N)C#N)N1CCN(c2ccccc2)CC1)N(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
MAPT P10636 6/20 0.44
HTT P42858 2/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PHGDH O43175 1/20 0.42
MGLL Q99685 1/20 0.42
NPC1 O15118 1/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 2/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
ALDH1A1 P00352 3/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5230594 1.00 MEN1 (0.45) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL5230605 1.00 MEN1 (0.45) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL5230967 0.95 AKR1C3 (0.42) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL5230976 0.95 AKR1C3 (0.42) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL5235406 0.82 ALDH1A1 (0.36) MEN1KMT2AMAPTCYP1A2CYP3A4
SCHEMBL5236086 0.81 CDK8 (0.46) MEN1KMT2AMAPTHTTCYP1A2
SCHEMBL5236079 0.81 CDK8 (0.46) MEN1KMT2AMAPTHTTCYP1A2
SCHEMBL5232551 0.77 MAPT (0.53) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL5234409 0.72 AKR1C3 (0.50) MEN1KMT2AMAPTHTTKDM4E
Phenylpiperazine SCHEMBL5667738 0.70 ADRB1 (0.56) MEN1KMT2AMAPTHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070219234-A1 Thienopyridine Derivatives SANKYO COMPANY, LIMITED (JP) 2007-09-20 US disclosed
EP-1764367-A1 THIENOPYRIDINE DERIVATIVES Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219234-A1 Thienopyridine Derivatives RASGRP1, NRAS, HRH3 MEN1 975/4885KMT2A 2660/4885MAPT 4452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.